Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Reich Samuel J
 2. Date of Event Requiring Statement (Month/Day/Year)
03/29/2007		 3. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [EXEG]
(Last)
(First)
(Middle)
EXEGENICS INC., 4400 BISCAYNE BOULEVARD, SUITE 900		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Executive VP
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MIAMI, FL 33137		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $.01 par value 490,921
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy)   (1) 03/27/2017 Common Stock 14,883 $ 0.6728 D  
Warrant (Right to Buy)   (1) 03/27/2017 Common Stock 14,883 $ 0.8473 D  
Warrant (Right to Buy)   (1) 03/27/2017 Common Stock 14,883 $ 1.0466 D  
Stock Option (Right to Buy)   (2) 12/11/2013 Common Stock 259,471 $ 0.04 D  
Stock Option (Right to Buy)   (3) 09/21/2014 Common Stock 233,524 $ 0.04 D  
Stock Option (Right to Buy)   (4) 02/15/2015 Common Stock 456,669 $ 0.04 D  
Stock Option (Right to Buy)   (5) 11/01/2015 Common Stock 287,686 $ 0.05 D  
Stock Option (Right to Buy)   (6) 01/01/2016 Common Stock 287,686 $ 0.05 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Reich Samuel J
EXEGENICS INC.
4400 BISCAYNE BOULEVARD, SUITE 900
MIAMI, FL 33137		       Executive VP  

Signatures

/s/ Samuel J. Reich 03/30/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These warrants are currently exercisable.
(2) 210,800 of these options are fully vested. The balance will vest monthly until fully vested in December 2007.
(3) 145,900 of these options are fully vested. The balance will best monthly until fully vested in September 2008.
(4) 237,847 of these options are fully vested. The balance will vest monthly until fully vested in February 2009.
(5) 95,894 of these options are fully vested. The balance will vest monthly until fully vested in November 2009.
(6) 83,905 of these options are fully vested. The balance will vest monthly until fully vested in January 2010.
 
Remarks:
All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.